Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

Heron Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Heron Therapeutics wird ein Gewinn- und Umsatzwachstum von 69.3% bzw. 17% pro Jahr prognostiziert, während der Gewinn pro Aktie um 70% pro Jahr wachsen soll.

Wichtige Informationen

69.3%

Wachstumsrate der Gewinne

70.0%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	25.0%
Wachstumsrate der Einnahmen	17.0%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	16 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Here's What Analysts Are Forecasting For Heron Therapeutics, Inc. (NASDAQ:HRTX) After Its Full-Year Results

Mar 15

Recent updates

Heron Therapeutics: Zynrelef Potentially Eases Shareholder Pain

Apr 16

Here's What Analysts Are Forecasting For Heron Therapeutics, Inc. (NASDAQ:HRTX) After Its Full-Year Results

Mar 15

Heron Therapeutics, Inc. (NASDAQ:HRTX) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Feb 15

Heron Therapeutics, Inc. (NASDAQ:HRTX) Held Back By Insufficient Growth Even After Shares Climb 27%

Dec 22

Need To Know: Analysts Just Made A Substantial Cut To Their Heron Therapeutics, Inc. (NASDAQ:HRTX) Estimates

Aug 11

Shareholders May Be A Bit More Conservative With Heron Therapeutics, Inc.'s (NASDAQ:HRTX) CEO Compensation For Now

Jun 11

Heron Therapeutics files for 12.4M common stock offering from shareholder

May 28

Is Heron Therapeutics (NASDAQ:HRTX) A Risky Investment?

May 19

Heron Therapeutics EPS misses by $0.03, misses on revenue

May 10

Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Shift From Loss To Profit

Mar 10

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:HRTX - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	217	40	29	32	3
12/31/2025	178	1	-6	-3	4
12/31/2024	148	-14	-33	-30	4
3/31/2024	132	-81	-45	-43	N/A
12/31/2023	127	-111	-60	-59	N/A
9/30/2023	123	-120	-100	-99	N/A
6/30/2023	118	-137	-128	-127	N/A
3/31/2023	114	-151	-129	-128	N/A
12/31/2022	108	-182	-149	-147	N/A
9/30/2022	98	-217	-156	-155	N/A
6/30/2022	95	-227	-174	-171	N/A
3/31/2022	90	-232	-209	-205	N/A
12/31/2021	86	-221	-206	-203	N/A
9/30/2021	86	-228	-216	-211	N/A
6/30/2021	83	-234	-204	-200	N/A
3/31/2021	83	-228	-198	-194	N/A
12/31/2020	89	-227	-192	-185	N/A
9/30/2020	103	-223	-167	-159	N/A
6/30/2020	126	-198	-149	-143	N/A
3/31/2020	140	-193	-116	-108	N/A
12/31/2019	146	-205	-132	-125	N/A
9/30/2019	140	-196	-138	-131	N/A
6/30/2019	117	-201	-153	-141	N/A
3/31/2019	98	-190	-190	-179	N/A
12/31/2018	77	-179	-201	-192	N/A
9/30/2018	59	-192	-212	-205	N/A
6/30/2018	47	-195	-213	-210	N/A
3/31/2018	39	-199	-184	-181	N/A
12/31/2017	31	-197	N/A	-170	N/A
9/30/2017	22	-183	N/A	-162	N/A
6/30/2017	13	-190	N/A	-157	N/A
3/31/2017	5	-190	N/A	-152	N/A
12/31/2016	1	-173	N/A	-134	N/A
9/30/2016	N/A	-156	N/A	-119	N/A
6/30/2016	N/A	-131	N/A	-102	N/A
3/31/2016	N/A	-110	N/A	-91	N/A
12/31/2015	N/A	-98	N/A	-79	N/A
9/30/2015	N/A	-87	N/A	-68	N/A
6/30/2015	N/A	-83	N/A	-68	N/A
3/31/2015	N/A	-79	N/A	-64	N/A
12/31/2014	N/A	-76	N/A	-60	N/A
9/30/2014	N/A	-70	N/A	-57	N/A
6/30/2014	N/A	-63	N/A	-50	N/A
3/31/2014	N/A	-60	N/A	-49	N/A
12/31/2013	N/A	-55	N/A	-41	N/A
9/30/2013	N/A	-50	N/A	-37	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: HRTX wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (2.4%).

Ertrag vs. Markt: HRTX wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.

Hohe Wachstumserträge: HRTX wird voraussichtlich in den nächsten 3 Jahren rentabel werden.

Einnahmen vs. Markt: HRTXDie Einnahmen des Unternehmens (17% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.4% pro Jahr).

Hohe Wachstumseinnahmen: HRTXDie Einnahmen des Unternehmens (17% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von HRTX in 3 Jahren voraussichtlich hoch sein wird

Heron Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus estimates of losses per share improve by 58%

Forecast breakeven date moved forward to 2025

Consensus estimates of losses per share improve by 51%

Here's What Analysts Are Forecasting For Heron Therapeutics, Inc. (NASDAQ:HRTX) After Its Full-Year Results

Heron Therapeutics, Inc. Re-Affirms Earnings Guidance for the Full Year 2024

Price target decreased by 8.7% to US$6.67

Recent updates

Consensus estimates of losses per share improve by 58%

Forecast breakeven date moved forward to 2025

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Heron Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

Heron Therapeutics, Inc. to Report Q1, 2024 Results on May 07, 2024

Heron Therapeutics: Zynrelef Potentially Eases Shareholder Pain

Consensus estimates of losses per share improve by 51%

Here's What Analysts Are Forecasting For Heron Therapeutics, Inc. (NASDAQ:HRTX) After Its Full-Year Results

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Heron Therapeutics, Inc. Re-Affirms Earnings Guidance for the Full Year 2024

Heron Therapeutics, Inc. to Report Q4, 2023 Results on Mar 12, 2024

Price target decreased by 8.7% to US$6.67

Heron Therapeutics, Inc. (NASDAQ:HRTX) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Heron Therapeutics, Inc. Announces FDA Approval of ZYNRELEF® Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures

Forecast to breakeven in 2026

Kevin Kotler Resigns as A Member of the Board of Directors of Heron Therapeutics, Inc., Effective December 31, 2023

Heron Therapeutics, Inc. (NASDAQ:HRTX) Held Back By Insufficient Growth Even After Shares Climb 27%

Consensus EPS estimates upgraded to US$0.90 loss

CEO & Director recently bought US$138k worth of stock

Price target decreased by 13% to US$6.50

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Heron Therapeutics, Inc. Provides Financial Guidance for the Year 2023 and 2024

Heron Therapeutics, Inc. to Report Q3, 2023 Results on Nov 14, 2023

New minor risk - Market cap size

Consensus EPS estimates fall by 30%

Second quarter 2023 earnings: EPS misses analyst expectations

Heron Therapeutics, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Heron Therapeutics, Inc. Announces Resignation of David Szekeres as Executive Vice President, Chief Operating Officer of the Company

Heron Therapeutics Announces Appointment of Ira Duarte as Chief Financial Officer

Heron Therapeutics Announces Appointment of William Forbes, Pharm.D. as Executive Vice President and Chief Development Officer

Heron Therapeutics, Inc. Announces Management Changes

Consensus EPS estimates fall by 17%

First quarter 2023 earnings: EPS misses analyst expectations

Heron Therapeutics, Inc. to Report Q1, 2023 Results on May 11, 2023

No longer forecast to breakeven

Full year 2022 earnings: EPS and revenues exceed analyst expectations

High number of new directors

Rubric Capital Management Engages with Heron Therapeutics

Forecast to breakeven in 2025

Heron Therapeutics, Inc. Provides Sales Guidance for the Full Year 2023

Forecast to breakeven in 2025

Heron Therapeutics, Inc. Announces the Submission of Supplemental New Drug Application for ZYNRELEF

Price target decreased to US$10.08

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Heron Therapeutics, Inc. Provides Sales Guidance for the Year 2022

Heron Therapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Heron Therapeutics, Inc. Announces U.S. FDA Approval of APONVIE™ (HTX-019) for Prevention of Postoperative Nausea and Vomiting

Heron wins FDA nod for post-operative agent to address nausea and vomiting

Heron Therapeutics, Inc. announced that it has received $76.499144 million in funding from Deep Track Capital, LP, Great Point Partners, LLC, Broadfin Holdings LLC

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Heron Therapeutics, Inc. announced that it expects to receive $76.499144 million in funding from Deep Track Capital, LP, Great Point Partners, LLC, Broadfin Holdings LLC and other investors

Is Heron Therapeutics (NASDAQ:HRTX) A Risky Investment?

Heron Therapeutics Q2 2022 Earnings Preview

Heron Therapeutics proposes 34% cut in workforce as part of cost reduction plan

Price target decreased to US$17.08

Heron Therapeutics, Inc. Provides Revenue Guidance for the Second Quarter and Full Year 2022

Heron Therapeutics, Inc. to Report Q1, 2022 Results on May 09, 2022

Heron Therapeutics, Inc., Annual General Meeting, May 24, 2022

Heron Therapeutics: Cash Is A Problem Again

Heron Therapeutics: Changing Strategy After Disappointing Earnings

Heron Therapeutics, Inc. Does Not Provide Financial Guidance for the Full Year 2022

Price target decreased to US$22.83

Heron Therapeutics, Inc. to Report Q4, 2021 Results on Feb 28, 2022

Health Check: How Prudently Does Heron Therapeutics (NASDAQ:HRTX) Use Debt?

Forecast to breakeven in 2024

Heron Therapeutics, Inc. Announces FDA Approval of a Significant Indication Expansion for ZYNRELEF

Third quarter 2021 earnings released: US$0.51 loss per share (vs US$0.64 loss in 3Q 2020)

High number of new and inexperienced directors

Heron Therapeutics: Looking For Signs Of The Bottom